A phase III, multicenter, randomized, double-blind clinical trial to study the safety and efficacy of the addition of sitagliptin (MK0431) to patients with type 2 diabetes mellitus who have inadequate glycemic control on insulin therapy (alone or in combination with metformin).

Trial Profile

A phase III, multicenter, randomized, double-blind clinical trial to study the safety and efficacy of the addition of sitagliptin (MK0431) to patients with type 2 diabetes mellitus who have inadequate glycemic control on insulin therapy (alone or in combination with metformin).

Completed
Phase of Trial: Phase III

Latest Information Update: 15 Sep 2017

At a glance

  • Drugs Sitagliptin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Merck & Co
  • Most Recent Events

    • 15 Sep 2017 Results (n=1299) of pooled analysis of 2 trials (NCT00395343 and NCT01462266) presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes
    • 10 Jun 2017 Biomarkers information updated
    • 01 Feb 2014 Results published in the Drugs and Aging.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top